Endowment Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$879K Buy
3,494
+186
+6% +$40K 0.34% 58
2026
Q1
$719K Sell
3,308
-41
-1% -$9.1K 0.32% 62
2025
Q4
$765K Sell
3,349
-91
-3% -$20.7K 0.35% 59
2025
Q3
$796K Buy
3,440
+1,016
+42% +$207K 0.36% 60
2025
Q2
$450K Sell
2,424
-82
-3% -$15.2K 0.23% 80
2025
Q1
$525K Buy
2,506
+218
+10% +$42.4K 0.34% 65
2024
Q4
$407K Sell
2,288
-15
-0.7% -$2.76K 0.27% 73
2024
Q3
$455K Buy
2,303
+87
+4% +$16.2K 0.3% 69
2024
Q2
$380K Buy
2,216
+15
+0.7% +$2.48K 0.28% 74
2024
Q1
$401K Sell
2,201
-100
-4% -$17.2K 0.3% 73
2023
Q4
$357K Sell
2,301
-326
-12% -$47.5K 0.3% 74
2023
Q3
$392K Buy
2,627
+394
+18% +$57.8K 0.35% 73
2023
Q2
$301K Sell
2,233
-1
-0% -$147 0.28% 96
2023
Q1
$356K Sell
2,234
-374
-14% -$57.2K 0.36% 71
2022
Q4
$422K Buy
2,608
+35
+1% +$5.37K 0.46% 57
2022
Q3
$345K Buy
2,573
+24
+0.9% +$3.44K 0.42% 67
2022
Q2
$390K Sell
2,549
-56
-2% -$8.56K 0.47% 59
2022
Q1
$422K Sell
2,605
-409
-14% -$59.4K 0.44% 56
2021
Q4
$408K Buy
+3,014
New +$356K 0.41% 50

Other funds holding ABBV

Endowment Wealth Management's ABBV Position: Q2 2026 in Review

Endowment Wealth Management increased its AbbVie (ABBV) stake by 5.6% in Q2 2026, buying an estimated $40K and bringing the position to 3,494 shares worth $879K. The position accounts for 0.34% of the portfolio, ranked #58.

Endowment Wealth Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Endowment Wealth Management held 3,494 shares of AbbVie worth $879K as of Q2 2026.
  • Endowment Wealth Management bought 186 AbbVie shares in Q2 2026, an estimated $40K.
  • AbbVie made up 0.34% of Endowment Wealth Management's portfolio in Q2 2026, its #58 holding.
  • Endowment Wealth Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Endowment Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.